I-SPY Phase 1b
Showing 1 - 25 of >10,000
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab
Recruiting
- HER2-positive Breast Cancer
- +17 more
- ALX148
- Fam-Trastuzumab Deruxtecan-Nxki
-
Chicago, Illinois
- +1 more
May 19, 2023
Healthy Trial in Pretoria (H107e, CAF®10b, H107e/CAF®10b - low adjuvant dose)
Not yet recruiting
- Healthy
- H107e
- +10 more
-
Pretoria, Gauteng, South AfricaAurum Institute
Sep 24, 2023
Advanced Malignancies Trial in Beijing (1A46 Drug Substance)
Not yet recruiting
- Advanced Malignancies
- 1A46 Drug Substance
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Aug 4, 2023
Gastroesophageal Adenocarcinoma Trial (toripalimab FOLFOX)
Not yet recruiting
- Gastroesophageal Adenocarcinoma
- toripalimab FOLFOX
- (no location specified)
Aug 3, 2023
Breast Tumors, Breast Cancer, Breast Tumors Trial in United States (Standard Therapy, AMG 386 with or without Trastuzumab, AMG
Recruiting
- Breast Neoplasms
- +10 more
- Standard Therapy
- +32 more
-
Birmingham, Alabama
- +35 more
Nov 17, 2022
B-Cell Malignancies Trial (TT-01488 Tablets)
Not yet recruiting
- B-Cell Malignancies
- TT-01488 Tablets
- (no location specified)
Jan 4, 2023
Relapsed/Refractory Large B-cell Lymphoma Trial (KITE-197, Cyclophosphamide, Fludarabine)
Not yet recruiting
- Relapsed/Refractory Large B-cell Lymphoma
- KITE-197
- +2 more
- (no location specified)
Oct 6, 2023
Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast Trial in Scottsdale (LS301-IT 0.025 mg/kg, LS301-IT 0.05 mg/kg, LS301-IT
Not yet recruiting
- Breast Cancer
- +2 more
- LS301-IT 0.025 mg/kg
- +3 more
-
Scottsdale, ArizonaIntegro Theranostics Research Site #1
Jun 2, 2023
Pulmonary Sarcoidosis Trial (XTMAB-16 or Placebo)
Not yet recruiting
- Pulmonary Sarcoidosis
- XTMAB-16 or Placebo
- (no location specified)
May 25, 2023
Herpes Zoster Trial in Bengbu (PEGIFNa1b, Placebo)
Completed
- Herpes Zoster
- PEGIFNα1b
- Placebo
-
Bengbu, Anhui, ChinaThe first affiliated hospital of bengbu medical college
Nov 28, 2022
Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-cell Lymphoma
- RC19D2 cell injection
-
Tianjin, Tianjin, ChinaHematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell Trial in United Kingdom (ALETA-001)
Not yet recruiting
- Lymphoma, Non-Hodgkin
- +4 more
-
Birmingham, United Kingdom
- +5 more
Sep 18, 2023
Cancer Trial (Antibody-Drug Conjugate)
Not yet recruiting
- Cancer
- Antibody-Drug Conjugate
- (no location specified)
Aug 23, 2023
Chronic Inducible Urticaria Trial in Canada, United States (Oral EP262)
Recruiting
- Chronic Inducible Urticaria
- Oral EP262
-
Tampa, Florida
- +5 more
Sep 18, 2023
Leukemia, Juvenile Myelomonocytic, JMML, JCML Trial (Trametinib, Azacitidine, Fludarabine)
Not yet recruiting
- Leukemia, Juvenile Myelomonocytic
- +4 more
- Trametinib
- +3 more
- (no location specified)
May 4, 2023
Breast Carcinoma, Colorectal Adenocarcinoma, Bladder Carcinoma Trial run by the National Cancer Institute (NCI) (Recombinant
Recruiting
- Breast Carcinoma
- +2 more
- Recombinant human IL-7-hyFc (NT-I7)
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Acute Myeloid Leukemia Trial in Houston (ASTX727, ASTX029-01)
Not yet recruiting
- Acute Myeloid Leukemia
-
Houston, TexasMD Anderson Cancer Center
Oct 27, 2023
Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Providence (TY-2136b)
Not yet recruiting
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
-
Providence, Rhode IslandRhode Island Hospital, Brown University
Mar 2, 2023
Refractory B-cell Acute Lymphoblastic Leukemia Trial in Houston (Mosunetuzumab)
Not yet recruiting
- Refractory B-cell Acute Lymphoblastic Leukemia
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2023
Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Beijing (JS203 for Injection)
Not yet recruiting
- Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
- JS203 for Injection
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Nov 11, 2022
Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma Trial in Dresden (MDC-CAR-BCMA001 (BCMA directed CAR
Not yet recruiting
- Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma
- MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
-
Dresden, GermanyTechnische Universität Dresden, NCT/UCC, Early Clinical Trial Un
Apr 19, 2023
Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small
Recruiting
- Relapsed or Refractory CD19+ B-cell Lymphoma
- +2 more
- TBI-2001
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jul 26, 2023